PortfoliosLab logoPortfoliosLab logo
ARWR vs. ULS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ARWR vs. ULS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arrowhead Pharmaceuticals, Inc. (ARWR) and UL Solutions Inc (ULS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ARWR achieves a 27.50% return, which is significantly higher than ULS's 16.58% return.


ARWR

1D
-3.06%
1M
0.79%
6M
22.10%
YTD
27.50%
1Y
431.39%
3Y*
35.96%
5Y*
4.09%
10Y*
30.88%
ALL TIME*
-0.69%

ULS

1D
-0.56%
1M
-5.52%
6M
30.90%
YTD
16.58%
1Y
28.31%
3Y*
5Y*
10Y*
ALL TIME*
54.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$205.45M$188.79M$175.31M
$63.17M$75.57M$90.09M

ARWR vs. ULS - Yearly Performance Comparison


2026 (YTD)20252024
ARWR
Arrowhead Pharmaceuticals, Inc.
27.50%253.14%-26.79%
ULS
UL Solutions Inc
16.58%59.33%46.87%

Correlation

The correlation between ARWR and ULS is 0.13, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.13

Correlation (All Time)
Calculated using the full available price history since Apr 12, 2024

0.15

Fundamentals

Market Cap

ARWR:

$11.92B

ULS:

$18.44B

EPS

ARWR:

-$2.16

ULS:

$1.71

PS Ratio

ARWR:

19.00

ULS:

6.01

PB Ratio

ARWR:

20.13

ULS:

13.99

Total Revenue (TTM)

ARWR:

$622.01M

ULS:

$3.11B

Gross Profit (TTM)

ARWR:

$529.27M

ULS:

$1.54B

EBITDA (TTM)

ARWR:

-$168.38M

ULS:

$725.35M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ARWR vs. ULS — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ARWR
ARWR Risk / Return Rank: 9999
Overall Rank
ARWR Sharpe Ratio Rank: 100100
Sharpe Ratio Rank
ARWR Sortino Ratio Rank: 9999
Sortino Ratio Rank
ARWR Omega Ratio Rank: 9898
Omega Ratio Rank
ARWR Calmar Ratio Rank: 100100
Calmar Ratio Rank
ARWR Martin Ratio Rank: 100100
Martin Ratio Rank

ULS
ULS Risk / Return Rank: 6666
Overall Rank
ULS Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
ULS Sortino Ratio Rank: 6363
Sortino Ratio Rank
ULS Omega Ratio Rank: 6565
Omega Ratio Rank
ULS Calmar Ratio Rank: 6868
Calmar Ratio Rank
ULS Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ARWR vs. ULS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and UL Solutions Inc (ULS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ARWRULSDifference
Sharpe ratioReturn per unit of total volatility

+6.08

Sortino ratioReturn per unit of downside risk

+4.52

Omega ratioGain probability vs. loss probability

1.70

1.16

+0.54

Calmar ratioReturn relative to maximum drawdown

17.83

1.08

+16.75

Martin ratioReturn relative to average drawdown

51.66

2.44

+49.21

ARWR vs. ULS - Sharpe Ratio Comparison

The current ARWR Sharpe Ratio is 6.69, which is higher than the ULS Sharpe Ratio of 0.62. The chart below compares the historical Sharpe Ratios of ARWR and ULS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ARWR vs. ULS - Drawdown Comparison

The maximum ARWR drawdown since its inception was -99.24%, which is greater than ULS's maximum drawdown of -24.34%. Use the drawdown chart below to compare losses from any high point for ARWR and ULS.


Loading charts...

Drawdown Indicators


ARWRULSDifference

Max Drawdown

Largest peak-to-trough decline

-99.24%

-24.34%

-74.90%

Max Drawdown (1Y)

Largest decline over 1 year

-24.64%

-24.34%

-0.30%

Max Drawdown (3Y)

Largest decline over 3 years

-74.70%

Max Drawdown (5Y)

Largest decline over 5 years

-87.89%

Max Drawdown (10Y)

Largest decline over 10 years

-88.96%

Current Drawdown

Current decline from peak

-47.91%

-12.50%

-35.41%

Average Drawdown

Average peak-to-trough decline

-81.07%

-6.01%

-75.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.49%

10.76%

-2.27%

Volatility

ARWR vs. ULS - Volatility Comparison

Arrowhead Pharmaceuticals, Inc. (ARWR) has a higher volatility of 23.10% compared to UL Solutions Inc (ULS) at 11.44%. This indicates that ARWR's price experiences larger fluctuations and is considered to be riskier than ULS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ARWRULSDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.10%

11.44%

+11.66%

Volatility (6M)

Calculated over the trailing 6-month period

39.03%

31.61%

+7.42%

Volatility (1Y)

Calculated over the trailing 1-year period

65.63%

42.62%

+23.01%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

64.63%

35.90%

+28.73%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

74.38%

35.90%

+38.48%

Dividends

ARWR vs. ULS - Dividend Comparison

ARWR has not paid dividends to shareholders, while ULS's dividend yield for the trailing twelve months is around 0.60%.


PositionTTM20252024
ARWR
Arrowhead Pharmaceuticals, Inc.
0.00%0.00%0.00%
ULS
UL Solutions Inc
0.60%0.66%0.75%

Financials

ARWR vs. ULS - Financials Comparison

This section allows you to compare key financial metrics between Arrowhead Pharmaceuticals, Inc. and UL Solutions Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


ARWR and ULS have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARWR has higher volatility (23.10%) compared to ULS (11.44%). In terms of maximum drawdown, ARWR dropped -99.24% vs ULS's -24.34%.

ARWR currently has the higher Sharpe Ratio (6.69 vs 0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ARWR and ULS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer